摘要
【目的】探讨贝伐珠单抗联合紫杉醇治疗晚期乳腺癌的疗效及对患者免疫功能的影响。【方法】本院收治的80例晚期乳腺癌患者,随机分为两组,每组40例。观察组采用紫杉醇+贝伐珠单抗治疗,对照组仅采用紫杉醇治疗。比较两组临床疗效、血清相关指标[血管表皮生长因子(VEGF)、碱性纤维细胞因子(bF-GF)]、肿瘤标志物[血清癌胚抗原(CEA)、糖类抗原125(CA125)]、免疫功能指标(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))的水平及不良反应发生情况。【结果】观察组患者总缓解率为75.00%(30/40),明显高于对照组的50.00%(20/40),且差异有统计学意义(P<0.05);治疗后,两组VEGF、bF-GF水平和CEA、CA125水平较治疗前均降低(P<0.05),且观察组上述指标水平均低于对照组(P<0.05);治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均较治疗前升高(P<0.05),且观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。【结论】在晚期乳腺癌患者中应用贝伐珠单抗联合紫杉醇化疗,能够改善晚期乳腺癌患者的免疫功能,有效降低肿瘤标志物及血清相关因子水平,临床疗效较好,且不增加不良反应,值得临床推广应用。
【Objective】To investigate the efficacy of bevacizumab combined with paclitaxel in the treatment of advanced breast cancer and its effect on patients'immune function.【Methods】Eighty patients with advanced breast cancer admitted to our hospital were randomly divided into two groups,with 40 patients in each group.The observation group was treated with paclitaxel^(+)bevacizumab,while the control group was treated with paclitaxel alone.The clinical efficacy,serum-related markers[Vascular Endothelial Growth Factor(VEGF),Basic Fibroblast Growth Factor(bF-GF)],tumor markers[Serum Carcinoembryonic Antigen(CEA),Carbohydrate Antigen 125(CA125)],and immune function indicators(CD3^(+),CD4^(+),CD4^(+)/CD8^(+))level changes and the incidence of adverse reactions in both groups were compared.【Results】The total remission rate of the observation group was 75.00%(30/40),which was significantly higher than 50.00%(20/40)of the control group.And the difference was statistically significant(P<0.05).After treatment,the levels of VEGF,bF-GF,CEA,and CA125 in both groups decreased compared to before treatment(P<0.05),and the aforementioned indicators in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)in both groups increased compared to before treatment(P<0.05),and the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group(P<0.05).The incidence of adverse reactions in both groups showed no statistical difference(P>0.05).【Conclusion】The use of bevacizumab combined with paclitaxel chemotherapy in advanced breast cancer can improve the immune function of patients,effectively reduce tumor markers and serum-related factors,and demonstrate good clinical efficacy.The combination treatment does not increase adverse reactions,which is worthy of clinical promotion and application.
作者
谭越
李纲
李雪莲
杨梅
TAN Yue;LI Gang;LI Xue-lian(Department of Oncology,Minhang Branch,Fudan University Affiliated Cancer Hospital,Shanghai 200240)
出处
《医学临床研究》
CAS
2023年第8期1132-1135,共4页
Journal of Clinical Research
基金
闵行区高层次专科骨干医师培养项目(编号:2020MZYS28)。
